US 11,986,475 B1
Compositions and methods for treating cancer
Chaemin Lim, New York, NY (US); Sridhar Vempati, Edison, NJ (US); Erden Banoglu, Ankara (TR); Burcu Caliskan, Ankara (TR); and Ozgur Sahin, Charleston, SC (US)
Assigned to A2A Pharmaceuticals, Inc., New York, NY (US); and OncoCube Therapeutics LLC, Wilmington, DE (US)
Filed by A2A Pharmaceuticals, Inc., New York, NY (US); and OncoCube Therapeutics LLC, Wilmington, DE (US)
Filed on Nov. 13, 2023, as Appl. No. 18/389,078.
Application 18/389,078 is a continuation of application No. PCT/US2023/016132, filed on Mar. 23, 2023.
Claims priority of provisional application 63/323,339, filed on Mar. 24, 2022.
Int. Cl. A61K 31/501 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/501 (2013.01) [A61P 35/00 (2018.01)] 28 Claims
 
1. A compound represented by formula Mc or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
E is aryl, heteroaryl, or heterocyclyl;
D is

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
X5 is N or CR8;
X6 is N or CR9;
R1 is H, alkyl, or benzyl;
R2, R5, R6, R7, R8, and R9 are each independently H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxy, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido.